Ortonne 1989.

Methods	A randomized controlled trial Double blind Efficacy Parallel design
Participants	Twenty four patients with systemic sclerosis Source of population: community Country: France Mean age: 53.7. All patients completed the trial.
Interventions	Ketanserin or identical placebo
Outcomes	Functional signs (VAS) Raynaud's phenomenon (i.e. severity, frequency of attacks, duration of pallor phase, Duration of cyanotic phase) Clinical signs (oral aperture, height, width, finger circumstance, SBP, DPB, Heart rate) Global assessments (mean functional index, global physician assessment)
Notes	Quality Score = 3